The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | Can venetoclax be used to treat multiple myeloma (MM)?
Philippe Moreau, MD, from the University Hospital of Nantes, Nantes, France, speaks about the potential of venetoclax in multiple myeloma (MM) treatment at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He discusses the current indications of this drug, and highlights that venetoclax is particularly effective in myeloma patients with the t(11,14) translocation. Prof. Moreau describes combination therapies including venetoclax, and speaks about the importance of further trials to determine the efficacy of venetoclax in different patient groups.
